BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06120283

Public ClinicalTrials.gov record NCT06120283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Study identification

NCT ID: NCT06120283
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: BeOne Medicines; Industry
Enrollment: 399 participants

Conditions and interventions

Conditions

Interventions

Anti-Diarrheal Agent Drug
BGB-43395 Drug
Elacestrant Drug
Fulvestrant Drug
Letrozole Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2023
Primary completion: Oct 31, 2028
Completion: Oct 31, 2028
Last update posted: Apr 14, 2026

2023 – 2028

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Sarah Cannon Research Institute (Scri) At Health One	Denver	Colorado	80218-1238	Recruiting
Florida Cancer Specialists and Research Institute	Lake Mary	Florida	32746-2115	Completed
Karmanos Cancer Institute	Detroit	Michigan	48201-2013	Completed
Washington University School of Medicine	St Louis	Missouri	63110-1010	Recruiting
Duke Cancer Center	Durham	North Carolina	27710-2000	Recruiting
James Cancer Hospital and Solove Research Institute	Columbus	Ohio	43210-1240	Recruiting
Scri Oncology Partners	Nashville	Tennessee	37203-1503	Recruiting
The University of Texas Md Anderson Cancer Center	Houston	Texas	77030-4009	Recruiting
Next Dallas	Irving	Texas	75039-2743	Recruiting
Next Oncology	San Antonio	Texas	78229-6028	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06120283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 14, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06120283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →